-
Mashup Score: 89
Given the low antitumour activity of existing treatment options in this patient population, trastuzumab deruxtecan might have the potential to fill a large unmet need in HER2-overexpressing NSCLC. Our findings support further investigation of trastuzumab deruxtecan in patients with HER2-overexpressing NSCLC.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Metastatic Breast Cancer Support and Education - Dana-Farber Cancer Institute | Boston, MA - 6 month(s) ago
One of the goals of the Ending Metastatic Breast Cancer for Everyone (EMBRACE) program is to provide resources and information to help guide patients through many situations and decisions. Throughout their journey, metastatic breast cancer patients in the EMBRACE program receive education and support from expert clinicians, other professionals, and one another.
Source: www.dana-farber.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Treatment Considerations for Previously Treated Patients with HER2 Positive Metastatic Breast Cancer - 6 month(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status - 6 month(s) ago
Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor that plays a carcinogenic role in breast cancer (BC) through gene amplification, mutation, or overexpression. Traditional…
Source: onlinelibrary.wiley.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
October is #BreastCancerAwarenessMonth! This review summarizes the necessity of developing #HER2 detection methods, and the clinicopathological and drug treatment characteristics of #BreastCancer patients with HER2-low/zero 🔓FREE to read until 31.10! ➡️https://t.co/IO10L8KPP1 https://t.co/1FkyqVLGGx
-
-
Mashup Score: 1Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer - 7 month(s) ago
HER2-mutant breast cancers acquire secondary HER2 mutations that drive resistance to HER2 tyrosine kinase inhibitors, which can be overcome by combined inhibition of HER2 and MEK.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 25
PURPOSE Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2–mutant (HER2m; defined as single-nucleotide variants and exon 20 insertions) metastatic non–small-cell lung cancer (mNSCLC). METHODS DESTINY-Lung02, a blinded, multicenter, phase II study, investigated T-DXd 5.4 mg/kg once every 3 weeks for the first time in previously treated (platinum-containing therapy) patients with HER2m mNSCLC and further assessed T-DXd 6.4 mg/kg once every 3 weeks in this population. The primary end point was confirmed objective response rate (ORR) per RECIST v1.1 by blinded independent central review. RESULTS One hundred fifty-two patients were randomly assigned 2:1 to T-DXd 5.4 or 6.4 mg/kg once every 3 weeks. As of December 23, 2022, the median duration of follow-up was 11.5 months (range, 1.1-20.6) with 5.4 mg/kg an
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
🔥🚨@OncoAlert Hot off the press, just published @JCO_ASCO, simultaneously with presentation @IASLC #WCLC23, results of #DESTINY-Lung02, Phase II Trial of #Trastuzumab Deruxtecan (T-DXd) in Patients With #HER2-Mutant Metastatic #NSCLC. #LCSM 👇🏼 https://t.co/7sUA5USKWs https://t.co/TA9Clbai4g
-
-
Mashup Score: 0Treatment Considerations for Previously Treated Patients with HER2 Positive Metastatic Breast Cancer - 8 month(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1New drug combo could treat some resistant breast cancers - 8 month(s) ago
A novel combination of drugs successfully killed breast cells carrying double mutations in the HER2 gene that had rendered them resistant to a commonly used cancer therapy, a study led by UT Southwestern Medical Center researchers showed.
Source: www.utsouthwestern.eduCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0HER2+ Early Breast Cancer Roundtable: Factors Guiding Treatment Before and After Surgery - 8 month(s) ago
This video highlights both disease- and patient-specific characteristics that may impact treatment options for the management of early breast cancer, including pre-surgery treatment outcomes, adverse events, chemotherapy de-escalation, and more.
Source: www.consultant360.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes - 8 month(s) ago
This review assesses current evidence on the prognostic or predictive effect of HER2 amplification/overexpression on anti-EGFR treatment outcomes in patients wi
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Results from DESTINY-Lung01: trastuzumab deruxtecan in #HER2 overexpressing cohort now @TheLancetOncol. T-DXd (HER2-ADC) 5.4mg/kg showed RR 34%, mPFS 6.7m with 5% ILD in HER2 overexpressing NSCLC. Activity, though not as much as HER2 mutant NSCLC. https://t.co/2G7z5NwFYd